Prothena Corp. (PRTA) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Prothena (PRTA) Pivotal Trial Readout Coming in 2H18 - Wedbush
February 19, 2016 9:47 AM ESTWedbush analyst, Heather Behanna, expects a potential catalyst for Prothena Corp (NASDAQ: PRTA) in 2H18 when data from the VITAL enrollment is released. A slip in the launch date pressures the price target to $77 but the analyst keeps the Outperform rating.
NEOD001 VITAL enrollment update sets up for pivotal trial readout in 2H18. At this time, Prothena anticipates enrollment to be complete in 2Q17 with data to follow in 12-18 months. As a reminder, VITAL is an event driven study enrolling newly diagnosed AL... More
